TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00764881
Drug: Microgynon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
Study: NCT00764881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
Study: NCT01214655
Drug: LY2523355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Study: NCT04234308
Drug: Catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
Study: NCT01696123
Drug: MLC601
Approvals — FDA: no, EMA: no, PMDA: no
Description: It was described
Study: NCT04688645
Drug: Balanced crystalloid solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
Study: NCT04688645
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
Study: NCT02762929
Drug: HTX-011A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011A (bupivacaine/meloxicam), via injection.
Study: NCT02762929
Drug: HTX-011B
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011B (bupivacaine/meloxicam), via injection or instillation.
Study: NCT02762929
Drug: HTX-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-002, via injection.
Study: NCT02762929
Drug: HTX-009
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-009, via injection.
Study: NCT01308203
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
Study: NCT01479075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02871011
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delivered as a footbath
Study: NCT00102219
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01511042
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A hormone that is normally present in your body, which regulates your blood pressure.
Study: NCT00002881
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01813617
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the cohort received medical treatment according to standard care.
Study: NCT02968602
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline capsules taken twice daily for two weeks.
Study: NCT00402077
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, three times a day
Study: NCT00657189
Drug: MEDI-545
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once; SC Placebo × 12 doses on other weeks
Study: NCT00657189
Drug: MEDI-545
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
Study: NCT00657189
Drug: MEDI-545
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
Study: NCT00657189
Drug: MEDI-545
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg every week × 13 doses
Study: NCT00657189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Placebo every week × 13 doses
Study: NCT02347059
Drug: Dopamine Agonists (pramipexole, ropirinole)
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparkinsonian medication
Study: NCT02736552
Drug: S-1 for 1 year
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year S-1 after D2 resection
Study: NCT01893515
Drug: PRC-4016
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01893515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00919295
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02207205
Drug: Blood drawn from indwelling catheters versus direct venipuncture
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of the source of blood samples on whole blood clotting time
Study: NCT03936036
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study: NCT01495000
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneous injection, single dose
Study: NCT01332487
Drug: 5ARI + AB
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Study: NCT02260661
Drug: AZD8835
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
Study: NCT02260661
Drug: AZD8835
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
Study: NCT04293393
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
Study: NCT04293393
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
Study: NCT04293393
Drug: LHRH Analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
Study: NCT00580450
Drug: Thymosin alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg sc once a day for 16 weeks
Study: NCT03198338
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline
Study: NCT03503604
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion, 400 mg/m2 every 2 weeks
Study: NCT05125640
Drug: Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, with 240 mL of water at dosing in sitting position
Study: NCT02904772
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV bolus methylprednisolone 1mg/kg half hour prior to administration
Study: NCT00758524
Drug: LCI699
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 oral capsules
Study: NCT00758524
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone oral capsules
Study: NCT00758524
Drug: LCI699-matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699-matching placebo oral capsules
Study: NCT00758524
Drug: Eplerenone-matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone-matching placebo oral capsules
Study: NCT02636218
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
Study: NCT02368964
Drug: GnRH agonist 0.2 mg + hCG 250 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for triggering
Study: NCT01144611
Drug: bIAP bolus and 8h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
Study: NCT01144611
Drug: placebo bolus and 8h infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
Study: NCT00634946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administrated into the nucleus pulposus of an intervertebral disc.
Study: NCT00935116
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery
Study: NCT01482416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group will use placebo once/day during 30 days
Study: NCT00004012
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04333160
Drug: JTA-004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo a single intra-articular injection of JTA-004 into the knee joint
Study: NCT01999920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One to two pills per day for 12 weeks
Study: NCT01722630
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03805386
Drug: Physician directed opioid prescribing
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
Study: NCT03805386
Drug: Patient directed opioid prescribing
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
Study: NCT04688671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT06160609
Drug: GSK3174998
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3174998 will be administered.
Study: NCT00002578
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002578
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02035111
Drug: Tianshu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04108897
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
Study: NCT02890173
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02890173
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03413462
Drug: Placebo of HS-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.
Study: NCT01644240
Drug: Placebo - saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT03099109
Drug: LY3321367
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03099109
Drug: LY3300054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01350271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
Study: NCT02906670
Drug: Sym013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
Study: NCT01240759
Drug: S-707106 Dose A
Normalized name: Horseman's Dream Fung-A-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: One S-707106 A tablet
Study: NCT01240759
Drug: S-707106 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: One S-707106 B tablet
Study: NCT01240759
Drug: Placebo A tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 Placebo A tablets
Study: NCT02000726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02000726
Drug: Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
Study: NCT01396668
Drug: gemcitabine, cisplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
Study: NCT03162250
Drug: DSTA4637S
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSTA4637S will be administered as an IV infusion at 3 dose levels.
Study: NCT03162250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to DSTA4637S IV infusion will be administered as specified.
Study: NCT03162250
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
Study: NCT04062669
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the Saline Placebo group will receive 2 doses of saline Placebo, administered intramuscularly Day 1 and 61.
Study: NCT03582462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
Study: NCT02897778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
Study: NCT03260556
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses
Study: NCT01977417
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01977417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01687894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo propofol \& placebo sevoflurane
Study: NCT01662778
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug just solvent
Study: NCT02045446
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy
Study: NCT04544774
Drug: AIT
Normalized name: Guaitab
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIT for airborn allergens (SCIT/SLIT)
Study: NCT00408512
Drug: thiazides
Normalized name: Thiazides, plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 25 mg per day
Study: NCT02142608
Drug: BR55
Normalized name: Band-Aid Ourtone BR55 Bandages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound contrast agent
Study: NCT04057729
Drug: IMP4297
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/capsule.
Study: NCT03983980
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied once daily
Study: NCT00839358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline solution
Study: NCT03727074
Drug: Efudex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical cream twice a day
Study: NCT01163201
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously on Day -7 and -6, 60 mg/kg
Study: NCT02783924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02265393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01629511
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02496182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet only with the excipients of the Pirfenidone tablet
Study: NCT03817125
Drug: Placebo for antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.
Study: NCT03817125
Drug: Matching Placebo for SER-401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
Study: NCT01582035
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
Study: NCT01582035
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
Study: NCT01582035
Drug: PegFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
Study: NCT02633007
Drug: CVT-301 (levodopa inhalation powder)
Normalized name: levodopa Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
Study: NCT02242253
Drug: Placebo-MDI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02242253
Drug: Placebo HandiHaler®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02687451
Drug: Oxymorphone HCl
Normalized name: oxymorphone HCl
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
Study: NCT02687451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
Study: NCT02877901
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet at bed time
Study: NCT00596531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 2 pills, tid, for 4 months
Study: NCT04166786
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.
Study: NCT04166786
Drug: Ethanol Solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.
Study: NCT04166786
Drug: Testosterone placebo (vaseline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.
Study: NCT04166786
Drug: Ethanol placebo (lemon-flavoured water)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
Study: NCT00350207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00663793
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once.
Study: NCT01269918
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
Study: NCT04145128
Drug: AG881
Normalized name: Agenebrutinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-881 tablets.
Study: NCT03743051
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered as matching placebo tablets in the fasted condition)
Study: NCT01350362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
Study: NCT00160303
Drug: Local Corticosteroid Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01640249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally